Provided by Tiger Trade Technology Pte. Ltd.

AstraZeneca PLC

160.12
+1.510.95%
Pre-market: 159.84-0.2800-0.17%09:23 EDT
Volume:2.46M
Turnover:393.68M
Market Cap:248.35B
PE:23.97
High:161.29
Open:159.12
Low:158.53
Close:158.61
52wk High:212.71
52wk Low:153.41
Shares:1.55B
Float Shares:1.50B
Volume Ratio:0.95
T/O Rate:0.16%
Dividend:3.17
Dividend Rate:1.98%
EPS(TTM):6.68
EPS(LYR):6.54
ROE:21.96%
ROA:8.21%
PB:4.94
PE(LYR):24.48

Loading ...

AstraZeneca PLC Stock Falls Monday, Underperforms Market

Dow Jones
·
Aug 25

AstraZeneca Rallies Friday, Outperforms Market

Dow Jones
·
Aug 22

AstraZeneca’s SELENE 3 Trial Targets Extra Weight-Loss Upside for AZN Investors

TIPRANKS
·
Aug 21

AstraZeneca PLC Stock Rises Thursday, Outperforms Market

Dow Jones
·
Aug 21

Dizhe Pharma Surpasses 500 Million Yuan in First-Half Revenue, Seals Global Exclusive Licensing Pact with AstraZeneca for Sunvozertinib

Deep News
·
Aug 20

Third Indication Approved in China for AstraZeneca's Ultomiris

Stock News
·
Aug 20

Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Aug 20

AstraZeneca PLC Stock (AZN) Moved Up by 3.40% on Aug 19: What Signal Does It Send?

TradingKey
·
Aug 20

Movement Alert|AstraZeneca PLC Rises 3.1% in Regular Trading, Multiple Positive Phase III Lung Cancer Results Coupled with Pharma Sector Strength

Market Focus
·
Aug 19

The Key to Pharma M&A: Never Shopping Hungry - Heard on the Street

Dow Jones
·
Aug 19

UBS Keeps Their Buy Rating on AstraZeneca (AZN)

TIPRANKS
·
Aug 19

AstraZeneca Rises Tuesday, Outperforms Market

Dow Jones
·
Aug 19

European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading

MT Newswires Live
·
Aug 18

Citi Keeps Their Buy Rating on AstraZeneca (AZN)

TIPRANKS
·
Aug 18

AstraZeneca's Biologic Therapy Receives Dual Indication Approval for Launch in China

Stock News
·
Aug 18

AstraZeneca PLC Stock Rises Monday, Outperforms Market

Dow Jones
·
Aug 18

AstraZeneca to discontinue eVOLVE-Lung02 Phase III trial

TIPRANKS
·
Aug 17

Breakthrough: AstraZeneca and Daiichi Sankyo's ADC Shows Strong Efficacy in First-Line Lung Cancer Therapy

Stock News
·
Aug 17

AstraZeneca (AZN) Gets a Buy from J.P. Morgan

TIPRANKS
·
Aug 17

AstraZeneca Discontinues Phase 3 Lung Cancer Trial for Volrustomig Combination

MT Newswires Live
·
Aug 17